Export 12 results:
Sort by: Author Title Type [ Year  (Desc)]
Mogahed, E. A., H. El-Karaksy, H. Abdullatif, N. Yasin, A. Nagy, S. A. Alem, H. G. E. deen, and M. S. El-Raziky, "Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals", The Journal of Pediatrics, 2021.
El-karaksy, H. M., E. Mogahed, R. El-Sayed, M. El-Raziky, M. Sheba, M. Besheer, H. Elkiki, and H. Ghita, "Focal hepatic lesions in Egyptian infants and children: the pediatric hepatologist perspective.", Minerva pediatrica, vol. 70, issue 1, pp. 35-45, 2018. Abstract

BACKGROUND: Hepatic focal lesions in the pediatric age group are diverse and can be broadly classified into congenital, neoplastic and infective. The aim of this paper was to describe the frequency, nature and clinical presentation of focal hepatic lesions from a pediatric hepatologist perspective.

METHODS: Data were retrieved from files of all cases with focal hepatic lesions presenting to the Pediatric Hepatology Unit, Cairo University Pediatric Hospital, from January 2006 to December 2013, after the study protocol was approved by the department research committee and the institution ethical committee.

RESULTS: Over an 8-year period, 38 cases had focal hepatic lesions. They constituted less than 1% of the 4475 new cases presenting to the unit over this period. The commonest lesion was hepatic hemangioma(s) (34%). Two-thirds were neoplastic lesions whether benign or malignant. Eighty percent were benign focal lesions. Infectious causes (fascioliasis and pyogenic liver abscess) accounted for 29% of cases. Hepatocellular carcinoma was the commonest malignant neoplasm; it occurred in 5 cases (13.2%) on top of a chronic liver disease. Hepatoblastoma was less common.

CONCLUSIONS: From the hepatologist perspective, pediatric focal hepatic lesions are more likely to be benign. Hepatic hemangiomas are the commonest. Infectious causes are common in a developing country like Egypt. Hepatocellular carcinoma is the commoner malignant neoplasm and usually develops on a diseased liver. Screening infants and children with chronic liver disease for development of hepatocellular carcinoma is mandatory. Hepatoblastoma is less likely to present to the pediatric hepatologist as it is referred immediately to the oncologist or onco-surgeon.

Ghobrial, C., E. A. Mogahed, and H. El-Karaksy, "Routine analysis of ascitic fluid for evidence of infection in children with chronic liver disease: Is it mandatory?", PloS one, vol. 13, issue 10, pp. e0203808, 2018. Abstract

Ascitic fluid infection is a major cause of morbidity and mortality in cirrhotic patients, requiring early diagnosis and therapy. We aimed to determine predictors of ascitic fluid infection in children with chronic liver disease. The study included 45 children with chronic liver disease and ascites who underwent 66 paracentesis procedures. Full history taking and clinical examination of all patients were obtained including fever, abdominal pain and tenderness and respiratory distress. Investigations included: complete blood count, C-reactive protein, full liver function tests, ascitic fluid biochemical analysis, cell count and culture. Our results showed that patients' ages ranged between 3 months to 12 years. Prevalence of ascitic fluid infection was 33.3%. Gram-positive bacteria were identified in six cases, and Gram-negative bacteria in five. Fever and abdominal pain were significantly more associated with infected ascites (p value = 0.004, 0.006). Patients with ascitic fluid infection had statistically significant elevated absolute neutrophilic count and C-reactive protein. Logistic regression analysis showed that fever, abdominal pain, elevated absolute neutrophilic count and positive C-reactive protein are independent predictors of ascitic fluid infection. Fever, elevated absolute neutrophilic count and positive C-reactive protein raise the probability of ascitic fluid infection by 3.88, 9.15 and 4.48 times respectively. The cut-off value for C-reactive protein for ascitic fluid infection was 7.2 with sensitivity 73% and specificity of 71%. In conclusion, prevalence of ascitic fluid infection in pediatric patients with chronic liver disease and ascites was 33.3%. Fever, abdominal pain, positive C-reactive protein and elevated absolute neutrophilic count are strong predictors of ascitic fluid infection. Therefore an empirical course of first-line antibiotics should be immediately started with presence of any of these predictors after performing ascitic fluid tapping for culture and sensitivity. In absence of these infection parameters, routine ascitic fluid analysis could be spared.

El-Karaksy, H., E. A. Mogahed, H. Abdullatif, C. Ghobrial, M. S. El-Raziky, N. El-Koofy, M. El-Shabrawi, H. Ghita, sherif Baroudy, and Sawsan Okasha, Mona Isa, "Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus-infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir.", Journal of pediatric gastroenterology and nutrition, vol. 67, issue 5, pp. 626-630, 2018. Abstract

OBJECTIVES: Recently, direct acting antivirals (DAAs), sofosbuvir (SOF) combined with ledipasvir (LED), were approved for treatment of hepatitis C virus (HCV)-infected children 12 years of age and older or weighting at least 35 kg for all HCV genotypes. The aim of this study was to assess the safety and efficacy of SOF/LED in genotype 4 HCV-infected Egyptian children and adolescents.

METHODS: This observational study included 40 consecutive HCV-infected children of age 12 to <18 years old or weighing >35 kg, both treatment-naive and treatment-experienced. All of the children were hepatitis B virus-negative and had normal renal functions and heart rate. Patients received oral, fixed-dose combination tablet of SOF/LED (400 mg SOF, 90 mg LED [Harvoni]) once daily for 12 weeks. Potential side effects were recorded at weeks 4, 8, and 12 weeks of treatment. The study primary outcome was sustained virological response 12 weeks (SVR12) after end-of-treatment.

RESULTS: The study included 40 children and adolescents, 24 were boys (60%); their age ranged between 11.5 and 17.5 years (mean 13.9 ± 1.5). Baseline viral load ranged between 9630 and 24,600,000 IU/mL. HCV RNA became negative in 39 patients (97.5%) at 4 weeks and in all patients (100%) at weeks 8, 12, and SVR12. Asthenia was the commonest side effect, reported in 52.5% followed by headache in 47.5%.

CONCLUSIONS: Treatment with all-oral DAAs (SOF/LED) for 12 weeks was well tolerated in Egyptian children and adolescents infected with genotype 4 HCV, with 100% SVR12 and negligible side effects.

H,  E. - K., E. - R. M. S, A. G, and M. E, "The effect of tailoring of cornstarch intake on stature in children with glycogen storage disease type III.", J Pediatr Endocrinol Metab , vol. 28, pp. 195-200, 2015.
H,  E. - K., M. E, E. - S. R, E. - R. M, S. M, B. M, E. H, and G. H, "Focal hepatic lesions in egyptian infants and children: the pediatric hepatologist perspective. ", Minerva Pediatr , 2015.
NH,  R., D. RK, M. EA, M. IA, A. Y. H, S. SA, and E. - K. HM, "Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4. ", Cytokine 2015, 2015.
EA,  M., G. MY, S. R, E. H, A. OM, and E. - K. H, "Skeletal and cardiac muscle involvement in children with glycogen storage disease type III", Eur J Pediatr 2015, 2015.
 El-Mougy FA, S. SA, E. MM, M. IA, E. - E. RA, E. AM, H. HM, S. DH, S. LH, S. HM, et al., "Gene mutations in Wilson disease in Egyptian children: Report on two novel mutations.", Arab J Gastroenterol , vol. 15, pp. 114-8, 2014.
H,  E. - K., A. G, E. - R. M, M. E, F. E, G. A, E. - M. F, and E. - H. A, "Glycogen storage disease type III in Egyptian children: a single centre clinico-laboratory study", Arab J Gastroenterol , vol. 15, pp. 63-7, 2014.
H,  H., E. - D. N, M. E, Y. N, and E. - K. H, "A child with rotor syndrome and Capillaria philippinensis: case report and review of literature. ", J Egypt Soc Parasitol , vol. 41, pp. 417-22, 2011.